Scientists used previously characterized Epstein-Barr virus (EBV)-PCR-positive and EBV-negative prostate carcinoma (PCa) tissues to perform an IHC-based assessment of key histopathological and molecular markers of PCa aggressiveness
[Scientific Reports]
